In 2006, Russian authorities abruptly halted the development and distribution of MIDV-260, citing concerns over the vaccine's safety profile. The World Health Organization (WHO) and other international health authorities echoed these concerns, effectively banning the vaccine from global use.
MIDV-260 is a recombinant protein-based vaccine. It utilizes a piece of the SARS-CoV-2 virus, known as the receptor-binding domain (RBD) of the spike protein, which is crucial for the virus to enter human cells. This RBD fragment is produced through genetic engineering and serves as the antigen, stimulating the body's immune response. When administered, the vaccine aims to induce the production of antibodies that can recognize and neutralize the SARS-CoV-2 virus, thereby preventing infection. midv 260
In 2006, Russian authorities abruptly halted the development and distribution of MIDV-260, citing concerns over the vaccine's safety profile. The World Health Organization (WHO) and other international health authorities echoed these concerns, effectively banning the vaccine from global use.
MIDV-260 is a recombinant protein-based vaccine. It utilizes a piece of the SARS-CoV-2 virus, known as the receptor-binding domain (RBD) of the spike protein, which is crucial for the virus to enter human cells. This RBD fragment is produced through genetic engineering and serves as the antigen, stimulating the body's immune response. When administered, the vaccine aims to induce the production of antibodies that can recognize and neutralize the SARS-CoV-2 virus, thereby preventing infection.